Back to News
Market Impact: 0.25
Atrium Therapeutics Secures $50M To Advance RNA-Based Heart Therapies
Source: Nasdaq
Healthcare & BiotechPrivate Markets & VentureCompany Fundamentals
Atrium Therapeutics announced a private placement with institutional investors expected to generate approximately $50 million in gross proceeds. The company is developing RNA therapeutics targeting the heart.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
RNA0.35
More News
- The world needs Ukraine’s grain. Its farmers are running out of reasons to plant
- Why is the Chinese stock market missing the AI rally
- Why is T-Mobile stock tumbling today?
- Tesla drops 'Full Self-Driving' brand name in Europe after regulator pushback
- SpaceX makes big move into wireless. These once 'obsolete' tech stocks could benefit
- Wall Street Week | Michigan Manufacturing, AI Debt Investments, Baby Bonds, Canadian Coal Fight